Clinical Notes
Double recurrence of double cancers: Rhabdomyosarcoma and secondary AML
Naoki Kajita,
Corresponding Author
Naoki Kajita
Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan
Correspondence: Naoki Kajita, MD, Tokyo Metropolitan Children’s Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo, 183-8561, Japan. Email: [email protected]
Search for more papers by this author Yuya Saito,
Yuya Saito
Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan
Search for more papers by this author Atsushi Makimoto,
Atsushi Makimoto
Division of Pathology and Laboratory Medicine, Tokyo Metropolitan Children Medical Center, Tokyo, Japan
Search for more papers by this author Satoshi Miyahara,
Satoshi Miyahara
Division of Pathology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Search for more papers by this author Yuki Yuza,
Yuki Yuza
Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan
Search for more papers by this author
Naoki Kajita,
Corresponding Author
Naoki Kajita
Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan
Correspondence: Naoki Kajita, MD, Tokyo Metropolitan Children’s Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo, 183-8561, Japan. Email: [email protected]
Search for more papers by this author Yuya Saito,
Yuya Saito
Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan
Search for more papers by this author Atsushi Makimoto,
Atsushi Makimoto
Division of Pathology and Laboratory Medicine, Tokyo Metropolitan Children Medical Center, Tokyo, Japan
Search for more papers by this author Satoshi Miyahara,
Satoshi Miyahara
Division of Pathology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Search for more papers by this author Yuki Yuza,
Yuki Yuza
Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan
Search for more papers by this author
First published: 04 June 2020
No abstract is available for this article.
Disclosure
The authors declare no conflicts of interest.
References
- 1Heyn R, Khan F, Ensign LG et al. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide in Intergroup Rhabdomyosarcoma StudyⅢ: an interim report. Med. Pediatr. Oncol. 1994; 23 (2): 99–106.
- 2Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J. Clin. Oncol. 2004; 22: 2510–11.
- 3Hale GA, Heslop HE, Bowman LC et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999; 24: 735–9.
- 4Leahey AM, Friedman DL, Bunin NJ. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplant 1999; 23: 21–5.
- 5Ezoe S. Secondary leukemia associated with anti-cancer agent, etoposide, a topoisomerase Ⅱ inhibitor. Int. J. Environ. Res. Public Health 2012; 9: 2444–53.
